|
EP1017823B1
(en)
|
1997-02-07 |
2004-07-14 |
Princeton University |
Engineered protein kinases which can utilize modified nucleotide triphosphate substrates
|
|
US6162613A
(en)
*
|
1998-02-18 |
2000-12-19 |
Vertex Pharmaceuticals, Inc. |
Methods for designing inhibitors of serine/threonine-kinases and tyrosine kinases
|
|
US7383135B1
(en)
|
1998-05-04 |
2008-06-03 |
Vertex Pharmaceuticals Incorporated |
Methods of designing inhibitors for JNK kinases
|
|
US6610483B1
(en)
*
|
1999-07-23 |
2003-08-26 |
Princeton University |
Methods for identifying cellular responses attributable to signaling molecule inhibition and inhibitors thereof
|
|
DE10024174A1
(de)
*
|
2000-05-17 |
2001-11-29 |
Gsf Forschungszentrum Umwelt |
Verfahren zum Selektieren von Inhibitoren für Enzyme
|
|
US7792645B2
(en)
*
|
2000-08-30 |
2010-09-07 |
The Salk Institute For Biological Studies |
Three-dimensional structure of chalcone isomerase and methods of use thereof
|
|
AU2002245133A1
(en)
*
|
2000-12-15 |
2002-07-30 |
The Salk Institute For Biological Studies |
Methods of producing polyketide synthase mutants and compositions and uses thereof
|
|
ATE433751T1
(de)
|
2001-04-30 |
2009-07-15 |
Vertex Pharma |
Inhibitoren von gsk-3 und kristallstrukturen von gsk-3beta-protein und -proteinkomplexen
|
|
US20060263800A1
(en)
*
|
2001-11-01 |
2006-11-23 |
Princeton University |
Engineered protein kinases which can utilize modified nucleotide triphosphate substrates
|
|
WO2003105723A2
(en)
*
|
2002-06-14 |
2003-12-24 |
The Salk Institute For Biological Studies |
Mutant plant caffeic acid/5-hydroxyferulic acid 3/5-0-methyltransferases (comt), methods for preparation and use thereof
|
|
AU2003267145A1
(en)
*
|
2002-09-13 |
2004-04-30 |
Irm, Llc |
Highly specific modulators of gtpases for target validation
|
|
KR20050059199A
(ko)
*
|
2002-09-30 |
2005-06-17 |
제네랩스 테크놀로지스, 인코포레이티드 |
Ｃ형 간염 바이러스 감염 치료용의 뉴클레오시드 유도체
|
|
US7429596B2
(en)
*
|
2003-06-20 |
2008-09-30 |
The Regents Of The University Of California |
1H-pyrrolo [2,3-D] pyrimidine derivatives and methods of use thereof
|
|
AU2004266227A1
(en)
|
2003-08-15 |
2005-03-03 |
Merck & Co., Inc. |
4-cycloalkylaminopyrazolo pyrimidine NMDA/NR2B antagonists
|
|
PT1811957E
(pt)
*
|
2004-10-19 |
2009-01-27 |
Krka Tovarna Zdravil D D Novo |
Composição farmacêutica sólida contendo cloridrato de donepezil
|
|
WO2006068760A2
(en)
*
|
2004-11-19 |
2006-06-29 |
The Regents Of The University Of California |
Anti-inflammatory pyrazolopyrimidines
|
|
US20090215080A1
(en)
*
|
2005-10-13 |
2009-08-27 |
Activesite Pharmaceuticals |
Methods for identification of inhibitors of enzyme activity
|
|
KR20120051760A
(ko)
*
|
2006-04-04 |
2012-05-22 |
더 리젠트스 오브 더 유니이버시티 오브 캘리포니아 |
키나제 길항물질
|
|
WO2008095140A1
(en)
*
|
2007-01-31 |
2008-08-07 |
Bids Trading, L.P. |
Electronic block trading system and method of operation
|
|
US20110160232A1
(en)
*
|
2007-10-04 |
2011-06-30 |
Pingda Ren |
Certain chemical entities and therapeutic uses thereof
|
|
SG187426A1
(en)
|
2008-01-04 |
2013-02-28 |
Intellikine Llc |
Certain chemical entities, compositions and methods
|
|
US8193182B2
(en)
|
2008-01-04 |
2012-06-05 |
Intellikine, Inc. |
Substituted isoquinolin-1(2H)-ones, and methods of use thereof
|
|
US8065217B2
(en)
*
|
2008-02-12 |
2011-11-22 |
Bids Trading, L.P. |
Real-time portfolio balancing and/or optimization system and method
|
|
WO2009114874A2
(en)
|
2008-03-14 |
2009-09-17 |
Intellikine, Inc. |
Benzothiazole kinase inhibitors and methods of use
|
|
US8637542B2
(en)
|
2008-03-14 |
2014-01-28 |
Intellikine, Inc. |
Kinase inhibitors and methods of use
|
|
WO2010006072A2
(en)
*
|
2008-07-08 |
2010-01-14 |
The Regents Of The University Of California |
Mtor modulators and uses thereof
|
|
CA2730106A1
(en)
|
2008-07-08 |
2010-01-14 |
Intellikine, Inc. |
Kinase inhibitors and methods of use
|
|
EP2346508B1
(en)
|
2008-09-26 |
2016-08-24 |
Intellikine, LLC |
Heterocyclic kinase inhibitors
|
|
ES2570429T3
(es)
|
2008-10-16 |
2016-05-18 |
Univ California |
Inhibidores de heteroaril quinasa de anillo condensado
|
|
US8476282B2
(en)
|
2008-11-03 |
2013-07-02 |
Intellikine Llc |
Benzoxazole kinase inhibitors and methods of use
|
|
CA2760791C
(en)
|
2009-05-07 |
2017-06-20 |
Intellikine, Inc. |
Heterocyclic compounds and uses thereof
|
|
JP5819831B2
(ja)
|
2009-08-17 |
2015-11-24 |
インテリカイン， エルエルシー |
複素環式化合物およびそれらの使用
|
|
US8980899B2
(en)
|
2009-10-16 |
2015-03-17 |
The Regents Of The University Of California |
Methods of inhibiting Ire1
|
|
CA2799579A1
(en)
|
2010-05-21 |
2011-11-24 |
Intellikine, Inc. |
Chemical compounds, compositions and methods for kinase modulation
|
|
EP2637669A4
(en)
|
2010-11-10 |
2014-04-02 |
Infinity Pharmaceuticals Inc |
Heterocyclic compounds and their use
|
|
EP3238722B1
(en)
|
2011-01-10 |
2019-03-13 |
Infinity Pharmaceuticals, Inc. |
Solid forms of isoquinolinones
|
|
AR085397A1
(es)
|
2011-02-23 |
2013-09-25 |
Intellikine Inc |
Combinacion de inhibidores de quinasa y sus usos
|
|
JP6027610B2
(ja)
|
2011-07-19 |
2016-11-16 |
インフィニティー ファーマシューティカルズ， インコーポレイテッド |
複素環式化合物及びその使用
|
|
CA2842190A1
(en)
|
2011-07-19 |
2013-01-24 |
Infinity Pharmaceuticals Inc. |
Heterocyclic compounds and uses thereof
|
|
CN103998442B
(zh)
|
2011-08-29 |
2016-09-14 |
无限药品股份有限公司 |
杂环化合物及其用途
|
|
AU2012341028C1
(en)
|
2011-09-02 |
2017-10-19 |
Mount Sinai School Of Medicine |
Substituted pyrazolo[3,4-D]pyrimidines and uses thereof
|
|
US8940742B2
(en)
|
2012-04-10 |
2015-01-27 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
|
US8828998B2
(en)
|
2012-06-25 |
2014-09-09 |
Infinity Pharmaceuticals, Inc. |
Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
|
|
SG11201502331RA
(en)
|
2012-09-26 |
2015-04-29 |
Univ California |
Modulation of ire1
|
|
EP2914296B2
(en)
|
2012-11-01 |
2021-09-29 |
Infinity Pharmaceuticals, Inc. |
Treatment of cancers using pi3 kinase isoform modulators
|
|
US9481667B2
(en)
|
2013-03-15 |
2016-11-01 |
Infinity Pharmaceuticals, Inc. |
Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
|
|
CA2907726A1
(en)
|
2013-03-22 |
2014-09-25 |
Millennium Pharmaceuticals, Inc. |
Combination of catalytic mtorc1/2 inhibitors and selective inhibitors of aurora a kinase
|
|
US10769725B1
(en)
|
2013-06-05 |
2020-09-08 |
Bids Trading, L.P. |
System and methods for optimizing the effectiveness of interaction between participants in an electronic trading environment
|
|
WO2015051241A1
(en)
|
2013-10-04 |
2015-04-09 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
|
UA121104C2
(uk)
|
2013-10-04 |
2020-04-10 |
Інфініті Фармасьютикалз, Інк. |
Гетероциклічні сполуки і їх застосування
|
|
NZ724368A
(en)
|
2014-03-19 |
2023-07-28 |
Infinity Pharmaceuticals Inc |
Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
|
|
WO2015160975A2
(en)
|
2014-04-16 |
2015-10-22 |
Infinity Pharmaceuticals, Inc. |
Combination therapies
|
|
WO2016054491A1
(en)
|
2014-10-03 |
2016-04-07 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
|
CN114230571B
(zh)
|
2015-09-14 |
2025-07-08 |
无限药品股份有限公司 |
异喹啉酮的固体形式、其制备方法、包含其的组合物及其使用方法
|
|
US10759806B2
(en)
|
2016-03-17 |
2020-09-01 |
Infinity Pharmaceuticals, Inc. |
Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors
|
|
US10919914B2
(en)
|
2016-06-08 |
2021-02-16 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
|
US11147818B2
(en)
|
2016-06-24 |
2021-10-19 |
Infinity Pharmaceuticals, Inc. |
Combination therapies
|
|
CN113194752A
(zh)
|
2018-06-01 |
2021-07-30 |
康奈尔大学 |
Pi3k相关疾病或病症的组合疗法
|
|
AU2020412779A1
(en)
*
|
2019-12-23 |
2022-06-23 |
Sanford Burnham Prebys Medical Discovery Institute |
Ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) modulators and uses thereof
|
|
WO2023133354A2
(en)
|
2022-01-10 |
2023-07-13 |
Southern Research Institute |
Development of potential antidotes for arsenicals
|